Literature DB >> 27631996

Barriers to Cancer Clinical Trial Participation Among Saudi Nationals: A Cross-Sectional Study.

Khalid M Almutairi1, Wadi B Alonazi2, Abdulaziz A Alodhayani3, Jason M Vinluan4, Mahaman Moussa5, Abdulrahman S Al-Ajlan6, Khalid Alsaleh7, Duna Alruwaimi6, Nader E Alotaibi2.   

Abstract

This study aims to determine the factors that act as barriers to Saudi cancer patients in participating in a clinical trial (CT). A total of 244 patients from two different tertiary level hospitals (King Khalid University Hospital and King Fahad Medical City Hospital) in Riyadh, Saudi Arabia, participated in this cross-sectional study. The participants were interviewed by a trained researcher between September and November 2015. All respondents answered a three-part questionnaire which includes demographics, clinical information, and questions related to awareness of CTs, willingness to participate, and factors affecting participation in CTs. The mean age of the participants was 50.83, and 57 % of the participants were females. Most of the participants (63.5 %) were currently being treated for cancer, and 28 % were diagnosed with breast cancer followed by colorectal cancer. Health status or quality of life was self-reported as acceptable by 27.9 % of the participants, and 25 % of the participants at stage II of cancer. The factors that act as barriers to Saudi cancer patients in participating in a CT can be categorized into patient- and physician-related factors. Patient factors include lack of awareness, misconception and fear in participating in CTs; physician-related factors comprise of lack of encouragement from physician to patients in participating in a CT. The study identified few major barriers to participation in CTs. Increased patient awareness and recruitment strategies are required to increase accrual of patients including training for physicians and disseminating easy-to-read tools to the public.

Entities:  

Keywords:  Barriers; Cancer clinical trials; Patient accrual; Saudi Arabia

Mesh:

Year:  2017        PMID: 27631996     DOI: 10.1007/s10943-016-0306-8

Source DB:  PubMed          Journal:  J Relig Health        ISSN: 0022-4197


  33 in total

1.  Steps and time to process clinical trials at the Cancer Therapy Evaluation Program.

Authors:  David M Dilts; Alan B Sandler; Steven K Cheng; Joshua S Crites; Lori B Ferranti; Amy Y Wu; Shanda Finnigan; Steven Friedman; Margaret Mooney; Jeffrey Abrams
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

2.  Does enrollment in cancer trials improve survival?

Authors:  Christopher J Chow; Elizabeth B Habermann; Anasooya Abraham; Yanrong Zhu; Selwyn M Vickers; David A Rothenberger; Waddah B Al-Refaie
Journal:  J Am Coll Surg       Date:  2013-02-13       Impact factor: 6.113

3.  National survival trends of young adults with sarcoma: lack of progress is associated with lack of clinical trial participation.

Authors:  Archie Bleyer; Michael Montello; Troy Budd; Scott Saxman
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

Review 4.  Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors.

Authors:  Edward J Mills; Dugald Seely; Beth Rachlis; Lauren Griffith; Ping Wu; Kumanan Wilson; Peter Ellis; James R Wright
Journal:  Lancet Oncol       Date:  2006-02       Impact factor: 41.316

5.  Attitudes, knowledge and barriers to participation in cancer clinical trials among rural and remote patients.

Authors:  Sabe Sabesan; Bjourn Burgher; Petra Buettner; Peter Piliouras; Zulfiquer Otty; Suresh Varma; Darshit Thaker
Journal:  Asia Pac J Clin Oncol       Date:  2010-11-03       Impact factor: 2.601

6.  Patient-derived determinants for participation in placebo-controlled clinical trials for fibromyalgia.

Authors:  Andrew J Holman; Moni Blazej Neradilek; David D Dryland; Richard A Neiman; Paul B Brown; Robert E Ettlinger
Journal:  Curr Pain Headache Rep       Date:  2010-12

7.  The impact of cancer and its treatment on physical activity levels and quality of life among young Hong Kong Chinese cancer patients.

Authors:  Katherine K W Lam; William H C Li; S Y Chiu; Godfrey C F Chan
Journal:  Eur J Oncol Nurs       Date:  2016-02-11       Impact factor: 2.398

8.  Attitudinal barriers to participation in oncology clinical trials: factor analysis and correlates of barriers.

Authors:  S Manne; D Kashy; T Albrecht; Y-N Wong; A Lederman Flamm; A B Benson; S M Miller; Linda Fleisher; J Buzaglo; N Roach; M Katz; E Ross; M Collins; D Poole; S Raivitch; D M Miller; T G Kinzy; T Liu; N J Meropol
Journal:  Eur J Cancer Care (Engl)       Date:  2014-01-28       Impact factor: 2.520

9.  A review of reporting of participant recruitment and retention in RCTs in six major journals.

Authors:  Merran Toerien; Sara T Brookes; Chris Metcalfe; Isabel de Salis; Zelda Tomlin; Tim J Peters; Jonathan Sterne; Jenny L Donovan
Journal:  Trials       Date:  2009-07-10       Impact factor: 2.279

10.  Knowledge, Attitudes and Perceptions of Saudis towards Participating in Clinical Trials.

Authors:  Mohamad A Al-Tannir; Nahid El-Bakri; Amani K Abu-Shaheen
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

View more
  3 in total

1.  Transparency and public accessibility of clinical trial information in Croatia: how it affects patient participation in clinical trials.

Authors:  Ivana Šolić; Ana Stipčić; Ivančica Pavličević; Ana Marušić
Journal:  Biochem Med (Zagreb)       Date:  2017-06-15       Impact factor: 2.313

2.  Knowledge of and attitudes toward clinical trials in Saudi Arabia: a cross-sectional study.

Authors:  Nedal Al-Rawashdeh; Rana Damsees; Majed Al-Jeraisy; Eman Al Qasim; Ahmad M Deeb
Journal:  BMJ Open       Date:  2019-10-22       Impact factor: 2.692

3.  Patient distrust in pharmaceutical companies: an explanation for women under-representation in respiratory clinical trials?

Authors:  Laurie Pahus; Carey Meredith Suehs; Laurence Halimi; Arnaud Bourdin; Pascal Chanez; Dany Jaffuel; Julie Marciano; Anne-Sophie Gamez; Isabelle Vachier; Nicolas Molinari
Journal:  BMC Med Ethics       Date:  2020-08-13       Impact factor: 2.652

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.